In the recently released Colliers 2024 Life Sciences Report, Philadelphia ranked #4 nationwide, with Boston, the San Francisco Bay Area and San Diego ranking first, second and third, respectively. According to the report, the ranking is based upon a dynamic score considering selected Industry Drivers (VC Funding, NIH Funding and Biomedical Degree Completions) as well as Real Estate Inventory/Demand (Inventory, Net Absorption).
In contrast to the slowdown in leasing observed across the nation, the report notes that Greater Philadelphia Area’s demand for incubator space by startup and early-stage companies remained healthy. Also highlighted were Philadelphia based companies that achieved notable funding events, with Aro Biotherapeutics and Penn spinouts Vivodyne and Vittoria Biotherapeutics collectively raising almost $100 million in Q4 2024. Read the full report here.